Maelstrom Research Staging | MIReCoV_LTC_residents_2_to_4_weeks_postdose

MIReCoV_LTC_residents_2_to_4_weeks_postdose_2

Networks -

Variables -

Associated study MIReCoV Contingency Table

Population

MIReCoV - LTC residents

The population is composed of Long Term Care (LTC) residents who were offered the mRNA-1273 COVID-19 vaccine on 4 January and 2 February 2021. Participants were selected if their COVID-19 status was confirmed by a polymerase chain reaction (PCR) test at the time of a COVID-19 outbreak.

Selection Criteria

Newborns

Twins

Countries

Canada

Territory

Ethnic Origin

Health Status

Other Criteria

Participants are long-term care residents.

Supplementary Information about selection criteria

By 28 March 2021, 81% of residents had received 2 vaccine doses and 6% of residents had received vaccine 1 dose.

Recruitment

Sources of recruitment

Specific population

Specific Population

Members of an association

Supplementary Information

Residents are recruited from their long-term care homes.

Number of Participants

Number of Participants

198

Number of Participants with Biological Samples

Supplementary Information about selection criteria

Biological samples were taken from PCR confirmed cases.

Uninfected during outbreak: 12 participants

Infected during outbreak: 5 participants

More info

Data Collection Event

MIReCoV - LTC residents - 2 to 4 weeks post-dose 2

Blood samples were collected.

More info

Collected Dataset / MIReCoV_LTC_residents_2_to_4_weeks_postdose_2

MIReCoV_LTC_residents_2_to_4_weeks_postdose_2

Population

MIReCoV - LTC residents

Data Collection Event

MIReCoV - LTC residents - 2 to 4 weeks post-dose 2

Files

Variables Classifications